Navigation Links
Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
Date:3/12/2009

CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) Three months ended Year ended December 31, December 31, 2008 2007 2008 2007 (unaudited) Revenue $28 $28 $111 $743 Operating expenses: Research and development 10,755 21,743 50,086 76,523 General and administrative 4,783 5,382 20,503 25,839 Total operating expenses 15,538 27,125 70,589 102,362 Loss from operations (15,510) (27,097) (70,478) (101,619) Interest income 712 1,717 3,619 6,461 Interest expense (1,161) (1,571) (5,156) (4,106) Gain from valuation of warrant liability 7,122 - 371 - Net loss ($8,837) ($26,951) ($71,644) ($99,264) Basic and diluted net loss per share ($0.09) ($0.32) ($0.79) ($1.20) Shares used in computation of basic and diluted net loss per share 95,109 83,051 90,357 82,531 December 31, December 31, 2008 2007 Balance Sheet Data: Cash and cash equivalents $59,523 $75,721 Short-term investments 45,638 27,115 Long-term investments 3,386 17,739 Total assets 147,204 161,662 Warrant liability 14,190 - Convertible senior subordinated Notes 85,2
'/>"/>
SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... San Diego, CA (PRWEB) September 18, 2014 ... promotions which include Sartorius/Biohit, Socorex, Capp, and ... working with volumes of 100 uL or less ... pharmaceutical, oncology, and forensic applications. , The ... of high quality and economic alternative products to ...
(Date:9/17/2014)... SAN FRANCISCO , Sept. 17, 2014 /PRNewswire/ ... patients receiving accelerated partial breast irradiation (APBI) via ... and those with positive lymph nodes could be ... for Radiation Oncology (ASTRO) guidelines place these patients ... an abstract at the 2014 ASTRO meeting, Beaumont ...
(Date:9/17/2014)... DIEGO and PRINCETON, N.J. ... (NASDAQ: OTCQB:AEMD), the pioneer in developing targeted therapeutic devices ... and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), disclosed ... 2014 Exosomes & SingleCell Analysis Summit. On ... Exosome Sciences will give a presentation entitled: "Exosomes: A ...
(Date:9/17/2014)... JH Technologies announces the grand ... JH Technologies, a leader in sales and support ... expanded partnership with Leica Microsystems into the Southern California ... solutions will be featured at the grand opening slated ... facility is located within the JH Technologies office’s at ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 2Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 3JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 2JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 3
... Calif., June 6 InterMune, Inc.,(Nasdaq: ITMN ) ... Financial Officer of InterMune, will present at the Goldman ... on,June 10, 2008 at 8:05 a.m. PDT (11:05 a.m. ... Needham & Company, LLC Biotechnology and,Medical Technology Conference in ...
... 5 BioTrends Research Group, Inc.,released its third ... management of psoriasis. This report is based on,responses ... Dermatologists in April,2008., According to the study, ... use of biologics for the treatment of psoriasis ...
... BioTrends Research Group, Inc. is,pleased to announce the ... is based on the results of an on-line ... France, Germany, Italy, and Spain.,The report focuses on ... In the ESA market, Amgen,s Aranesp is ...
Cached Biology Technology:InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences 2Dermatologists Report Increased Use of Biologics in the Treatment of Psoriasis 2New Study by BioTrends Highlights Practice Management Shifts Among European Nephrologists 2
(Date:9/17/2014)... learned a great deal about complex social behavior by ... something to teach too. , With their unusually large ... parrots live in a complex social environment---not merely in ... or ants, but in a dynamic setting of alliances ... intelligent mammals: dolphins, whales, primates, and social carnivores, like ...
(Date:9/16/2014)... the Columbia Center for Children,s Environmental Health at the ... demonstrate an association between childhood asthma and prenatal exposure ... household products. Results appear online in the journal ... mothers exposed during pregnancy to higher levels of the ... a 72 percent and 78 percent increase in risk ...
(Date:9/16/2014)... North American Menopause Society (NAMS) has published its ... midlife womenon everything from hot flashes to heart ... Society Recommendations for Clinical Care of Midlife Women," ... Menopause . This is the first, comprehensive ... midlife women freely available to all clinicians who ...
Breaking Biology News(10 mins):Being social: Learning from the behavior of birds 2Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3
... the results of the Oats at 10 Years study, marking ... claim that oats, as part of an overall heart healthy ... written by Mark B. Andon, PhD, and James W. Anderson, ... claim, theorizing that foods containing whole-oat sources of soluble fiber ...
... University bioengineer Jennifer West is being recognized today with ... the O,Donnell Award from The Academy of Medicine, Engineering ... given for excellence in medical, scientific and engineering research, ... statue. West, a pioneer in the field of biomaterials ...
... of Alberta for those who may have overindulged during the recent ... a way to reduce the amount of bad cholesterol and fatty ... metabolizes, a key discovery that could lead to new drugs to ... disease related to obesity. In a series of recently ...
Cached Biology News:Rice's West honored as one of Texas' best researchers 2Rice's West honored as one of Texas' best researchers 3University of Alberta researchers report breakthrough in lowering bad cholesterol, fatty acid levels 2
... The Sub-Plates are E.Coli glycerol stocks contained ... contains 50 cDNA clones with approximately 5,000 ... the a master plate well, the corresponding ... PCR to identify the positive well(s). Cells ...
... 0.9 ml per liter of urine will give ... or BMD dipstick. ,Certification: The Donors are ... found to be NEGATIVE for HbsAg, HCV, HIV-1 ... approved FDA methods. THIS MATERIAL IS SOLD FOR ...
One controller two vessel system suitable for early stage of fermentation, and small scale, Application : cultivation of microorganisms and human or animal cells...
... light production by luciferase-cDNA transfected cell lines ... in the development of reporter gene assays ... an indicator for the transcription of other ... is due to advantages such as high ...
Biology Products: